Biogen Non-GAAP EPS of $3.39 beats by $0.02, revenue of $2.74B beats by $120M
Biogen press release
(NASDAQ:BIIB): Q4 Non-GAAP EPS of $3.39  beats by $0.02.
Revenue of $2.74B (-3.9% Y/Y)  beats by $120M.

FY22 Outlook: Revenue of $9.7B-$10B vs. consensus of $10.33B.
Non-GAAP EPS of $14.25-$16.00 vs. consensus of $18.69.
Non-GAAP R&D expense is expected to be between $2.2 billion and $2.3 billion.

NonGAAP SG&A expense is expected to be between $2.5 billion and $2.6 billion.
The company expects that we will utilize a portion of the remaining share repurchase authorization of $2,800 million through the end of 2022.